Back Bay Sponsors 2019 Yale Innovation Summit

Back Bay Sponsors 2019 Yale Innovation Summit

We’re proud to support academic innovation with our ongoing work around academic-industry partnering and through meaningful opportunities to bring together academic technology and commercial development.

The 2019 Yale Innovation Summit highlights investable innovations coming out of Yale labs and features a technology, Connecticut innovations, and biotech track for those interested in commercializing ideas for drug discovery and biological therapeutics. Back Bay will join a panel discussion on hot areas for biotech investing.

See the program, keynote speakers and panel topics at

Back Bay provides career mentoring and sponsorship to the Johns Hopkins Graduate Consulting Club

Back Bay is proud to sponsor the 9th Johns Hopkins Graduate Consulting Club Healthcare Case Competition, open to fellows at Johns Hopkins and other major universities around the world. The competition provides opportunities to practice solving real business problems, hone consulting skills, and work with consultants from top firms for mentorship.

JHGCC 9th Healthcare Case Competition – Friday, April 26th, 2019 Registration and information:

Transaction strategy: Is rNPV Overvalued?

Transaction strategy: Is rNPV Overvalued?

The underlying premise at Back Bay Life Science Advisors is that any accurate asset or company valuation must be derived from a fundamental understanding of the scientific, clinical, and commercial aspects of the financial models in use. Disciplined deal-making also considers external factors: the specific strategic fit and competitive intensity regarding any company or asset. For all these reasons, we deploy several methodologies to evaluate clinical-stage programs.

Read more »

Back Bay in the Boston Business Journal

Boston biotech financing and innovation flow are at all-time highs and “the fight over local talent is fueling scientific innovation and creating a financial boon for executives and employees,” according to the Boston Business Journal.

This month, Back Bay CEO, Jonathan P. Gertler, spoke with the Journal about the demand for life science executives in Greater Boston, and the value of a strong executive team in building a successful biotech company.

The Boston Business Journal: Biotech, in motion: Demand for life science execs fuels game of musical chairs

Back Bay at BIO-Europe Spring, Vienna

Back Bay strategy and transaction teams join LISAvienna, The Vienna Business Agency and 2,486 delegates at BIO-Europe Spring for partnering and presentations on the latest innovations and technologies by global pharma, biotech, and academic organizations.

Attending BIO-Europe and looking for strategic guidance on complex decisions around commercial, R&D, corporate development, or transactional opportunities? Connect with us in Vienna,

BIO-Europe, March 25–27, 2019

Messe Wien Exhibition and Congress Center,
Vienna, Austria

Back Bay Life Science Advisors in Xconomy

Xconomy recently reported that Gossamer Bio will return to a conventional IPO approach: “With SEC Reopened, Gossamer Bio Turns Back from Alternative IPO Path.”

Back Bay managing director and M&A expert, Vasilios Kofitsas noted that “a company that decides to take the fixed-price route is likely very comfortable with its valuation—and with its disclosures to investors.  

There’s certainly risk from a company perspective should you go this route and price successfully – and the SEC comes back and notices it has issues with lack of disclosures, for example.

. . . also, there is market risk: Investors have to be really comfortable with your disclosures as well. This is a risk you don’t take in a traditional IPO, since it has been cleared by the SEC, for all intents and purposes.”

Read about Gossamer Bio at

Related links:

Xconomy – With SEC Reopened, Gossamer Bio Turns Back from Alternative IPO Path

Asia Opens Its Doors for Pre-Revenue Biotechs

Asia Opens Its Doors for Pre-Revenue Biotechs

By Ned Benning, Analyst, Back Bay Life Science Advisors

One of the primary axioms at Back Bay Life Science Advisors is that assets must find the right form of capital. Venture is not right for every academic-derived technology. Going public is not right for every growing company or late-stage biotech. Geographic variation can bring different timelines, different IRR hurdles, and different ecosystem mandates. Capital sources are forever shifting, and lately, investment from China has been looming large on the radar screen for U.S. biotech. We see this as a good thing. Read more »